Skip to main content

Effect of fragmented Lactobacillus amylovorus CP1563 on lipid metabolism in overweight and mildly obese individuals: a randomized controlled trial

  • 2016-05-23
  • Microbial Ecology in Health & Disease 27(0)
    • F. Nakamura
    • Y. Ishida
    • K. Aihara
    • D. Sawada
    • Nobuhisa Ashida
    • Tomonori Sugawara
    • Yumeko Aoki
    • Isao Takehara
    • Kazuhiko Takano
    • S. Fujiwara

Abstract

Background: Previously, we showed that fragmented Lactobacillus amylovorus CP1563 (CP1563) functions as a dual agonist of peroxisome proliferator-activated receptor α and γ in vitro and in vivo.

Objective: Here, we examined the safety and effect of CP1563 ingestion on body fat in obese class I participants in a double-blinded, placebo-controlled, randomized clinical trial (RCT).

Design: In the RCT, 200 participants with a body mass index (BMI) of 25-30 kg/m(2) consumed test beverages with or without 200 mg of CP1563 daily for 12 weeks. In total, 197 subjects completed the study without any adverse effects.

Results: Body fat percentage, whole body fat, and visceral fat were significantly decreased in the test group compared with the placebo group (p<0.001, p<0.001, and p<0.001, respectively). Triglycerides, total cholesterol, LDL-cholesterol, and diastolic blood pressure showed significant reductions in the test group compared with the placebo group (p<0.001, p<0.001, p<0.001, and p<0.001, respectively). Additionally, significant differences in the changes in blood glucose, insulin, homeostasis model assessment-insulin resistance (HOMA-IR), and uric acid were observed between the two groups (p<0.001, p=0.004, p<0.001, and p<0.001, respectively). Improvements in anthropometric measurements and markers were observed in obese class I subjects in the test group.

Conclusions: Daily consumption of beverages containing fragmented CP1563 for 12 weeks by obese class I subjects improved anthropometric measurements and markers related to lipid and glucose metabolism without any adverse effects. These results suggest that the consumption of foods containing fragmented CP1563 reduces body fat and prevents metabolic syndrome.

Keywords: PPARα/γ dual agonist; biogenics; fragmented lactic acid bacteria; paraprobiotics; visceral fat.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus amylovorusImproved Blood Glucose LevelsBeneficial
Moderate
Lactobacillus amylovorusImproved Insulin LevelsBeneficial
Moderate
Lactobacillus amylovorusImproved Insulin SensitivityBeneficial
Large
Lactobacillus amylovorusReduced Body Fat PercentageBeneficial
Large
Lactobacillus amylovorusReduced Diastolic Blood PressureBeneficial
Large
Lactobacillus amylovorusReduced Low-Density Lipoprotein LevelBeneficial
Large
Lactobacillus amylovorusReduced Total Cholesterol LevelsBeneficial
Large
Lactobacillus amylovorusReduced Triglyceride LevelsBeneficial
Large
Lactobacillus amylovorusReduced Uric Acid LevelsBeneficial
Large
Lactobacillus amylovorusReduced Visceral FatBeneficial
Large
Lactobacillus amylovorusReduced Whole Body FatBeneficial
Large

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.